Invea Therapeutics, Inc filed a Form S-1 registration statement for an initial public offering on December 15, 2025. As of November 6, 2026, its registration was withdrawn. It says it will list on Nasdaq Capital Market under the symbol INAI (Form RW, March 6, 2026).
Sell to companies like Invea Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Invea Therapeutics, Inc filed a Form S-1 registration statement for an initial public offering on 2025-12-15. It has amended it 3 times. It asked for the registration statement to be withdrawn on 2026-03-06. Each fact below is quoted from the filing named with it.
Also on the record for Invea Therapeutics, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 10, 2025 | Form D, private offering | $120K sold | Form D page | Source |
| April 9, 2025 | Form D, private offering | $300K sold | Form D page | Source |
Check before you invest in Invea Therapeutics, Inc: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Invea Therapeutics, Inc and the records around it.
Invea Therapeutics, Inc elsewhere on the record
- Form D filing Dec 2025
- Form D filing Apr 2025
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q1 2026, newest first.
- FARLONG HOLDING Corp (Mar 2026)
- Innovation Beverage Group Ltd (Mar 2026)
Watch Invea Therapeutics, Inc
Get an email when Invea Therapeutics, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Invea Therapeutics, Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Invea Therapeutics, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Invea Therapeutics, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
We have applied to list our shares of common stock on the Nasdaq Capital Market, or Nasdaq, under the symbol “INAI.” It is a condition to the closing of this offering that our shares of common stock shall have been approved for listing on Nasdaq.From the S-1/A filed 2026-01-27
Price range
This is a firm commitment initial public offering of 3,200,000 shares of common stock, par value $0.0001 per share, of Invea Therapeutics, Inc. The anticipated initial public offering price will be between $10.00 and $12.00 per share of common stock.From the S-1/A filed 2026-01-27
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash as follows:From the S-1/A filed 2026-01-27
Net loss or income
Our net losses were $2.9 million and $5.4 million for the nine months periods ended September 30, 2025 and 2024, respectively, and $6.3 million and $9.9 million for the years ended December 31, 2024 and 2023, respectively.From the S-1/A filed 2026-01-27
Withdrawal
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “ Securities Act ”), Invea Therapeutics, Inc. (the “ Registrant ”) hereby respectfully requests that the U.S. Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Registrant’s Registration Statement on Form S-1 (File No. 333-292131) together with all exhibits and amendments thereto (collectively, the “ Registration Statement ”) initially filed with the Commission on December 15, 2025 and declared effective by the Commission on January 30, 2026 at 2:00 p.m.From the RW filed 2026-03-06
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-12-15 | Registration statement filed | S-1 |
| 2026-01-07 | Registration statement amended | S-1/A |
| 2026-01-23 | Registration statement amended | S-1/A |
| 2026-01-27 | Registration statement amended | S-1/A |
| 2026-03-06 | Request to withdraw a registration (Form S-1) | RW |
Tools for this story
Each opens in a new tab, filled in for Invea Therapeutics, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.